In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Prognosis and cost-effectiveness of cardiac rehabilitation
Session

Event : ESC Congress 2016

Topic : Rehabilitation: Outcomes

  • Session type : Moderated Posters
  • Date : 29 August 2016
  • Time : 10:05 - 10:55

7 presentations in this session

Mortality benefit of cardiac rehabilitation after myocardial infarction in the modern era

Event : ESC Congress 2016

  • Session : Prognosis and cost-effectiveness of cardiac rehabilitation
  • Speaker : J Klein (Jerusalem,IL)

Participation in exercise-based cardiac rehabilitation is associated with improved levels of risk factors in myocardial infarction survivors

Event : ESC Congress 2016

  • Session : Prognosis and cost-effectiveness of cardiac rehabilitation
  • Speaker : I Sjolin (Falsterbo,SE)

Determinants and outcome of drop-out in outpatient cardiac rehabilitation

Event : ESC Congress 2016

  • Session : Prognosis and cost-effectiveness of cardiac rehabilitation
  • Speaker : S Pardaens (Aalst,BE)

The benefits of cardiac rehabilitation in coronary artery disease: does the weight matter?

Event : ESC Congress 2016

  • Session : Prognosis and cost-effectiveness of cardiac rehabilitation
  • Speaker : M Braga (Porto,PT)

Cost effectiveness analysis of a cardiac rehabilitation program after an acute coronary syndrome

Event : ESC Congress 2016

  • Session : Prognosis and cost-effectiveness of cardiac rehabilitation
  • Speaker : R Andion Ogando (Palencia,ES)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are